BioStock: Saniona on the paused Tesomet programmes and restructuring

Saniona has announced a voluntary pause of the two phase IIb clinical trials with Tesomet and a reduction of its workforce by approximtely 30 per cent, entirely due to funding limitations. While pursuing financing and/or partnering options that could allow Tesomet to advance, Saniona will be focusing on its other assets SAN711 and SAN903. The market reacted strongly, and the stock slumped by about 60 per cent during last week. Biostock reached out to CEO Rami Levin for a comment.

Read the full interview with Rami Levin at biostock.se:

https://www.biostock.se/en/2022/04/saniona-on-the-paused-tesomet-programmes-and-restructuring/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/